Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S lessened its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 61.6% during the fourth quarter, HoldingsChannel reports. The firm owned 64,296 shares of the company’s stock after selling 102,926 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Teva Pharmaceutical Industries were worth $2,007,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of TEVA. Allworth Financial LP lifted its stake in shares of Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after purchasing an additional 329 shares in the last quarter. Grove Bank & Trust lifted its stake in shares of Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after purchasing an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after purchasing an additional 345 shares in the last quarter. Global Retirement Partners LLC lifted its stake in shares of Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after purchasing an additional 292 shares in the last quarter. Finally, 1620 Investment Advisors Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 1,823.2% in the fourth quarter. 1620 Investment Advisors Inc. now owns 1,577 shares of the company’s stock worth $49,000 after acquiring an additional 1,495 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the sale, the executive vice president owned 172,184 shares in the company, valued at $6,131,472.24. This represents a 47.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Richard Daniell sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total value of $1,062,000.00. Following the sale, the executive vice president owned 55,755 shares in the company, valued at $1,973,727. The trade was a 34.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 421,470 shares of company stock valued at $14,570,945 over the last three months. Company insiders own 0.54% of the company’s stock.

Analysts Set New Price Targets

TEVA has been the topic of several recent analyst reports. The Goldman Sachs Group boosted their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday. Barclays boosted their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. UBS Group boosted their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Finally, Bank of America boosted their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $41.78.

Teva Pharmaceutical Industries Trading Down 2.8%

Shares of NYSE TEVA opened at $33.24 on Tuesday. The stock’s 50 day moving average price is $32.89 and its two-hundred day moving average price is $31.74. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35. The stock has a market capitalization of $38.22 billion, a P/E ratio of 24.99, a PEG ratio of 3.49 and a beta of 0.84. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The firm had revenue of $3.98 billion for the quarter. On average, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.